NYSE:PSN

Parsons Corporation (PSN): Q2 Earnings, Upgrade, & Outlook

Font: Financial Modeling Prep  • Aug 02, 2026

Market Chart

Parsons Corporation (NYSE: PSN) Stock: Analyzing Performance and Future Outlook

  • Jefferies upgraded Parsons Corporation (NYSE: PSN) from “Hold” to “Buy” but lowered its price target from $60.00 to $52.00. Based on the stock’s price of $44.21, the new target implies potential upside of approximately 17.6%.
  • The company faced significant operational and financial challenges, including reduced full-year guidance and substantial charges that contributed to a sharp decline in its stock price.
  • Parsons reported adjusted diluted EPS of ($0.06), compared with the analyst estimate of $0.76, representing a shortfall of $0.82 per share.
  • Despite these setbacks, Parsons Corporation continues to show strong underlying demand. Contract awards increased 24% year over year to approximately $1.9 billion, while the company reported a 1.2x book-to-bill ratio.

Parsons Corporation (NYSE: PSN) is a leading technology solutions provider serving the defense sector, intelligence community, and critical infrastructure markets. The company’s stock has been highly volatile over the past year, trading between $36.26 and $89.50. Its market capitalization is approximately $4.72 billion.

On August 3, 2026, Jefferies upgraded Parsons Corporation to a “Buy” rating from “Hold.” However, the firm reduced its price target to $52.00 from $60.00. The new target implies potential upside of approximately 17.6% from the stock’s recent price of $44.21.

Parsons’ second-quarter 2026 results were affected by significant charges and portfolio-shaping actions. The company reported revenue of approximately $1.6 billion, down 1% year over year. Adjusted diluted EPS was ($0.06), compared with the analyst consensus estimate of $0.76. The company’s GAAP diluted EPS was ($0.14).

The EPS shortfall was primarily linked to $118 million in charges related to portfolio actions and a joint venture program. Excluding these charges, adjusted EBITDA increased 8% year over year to $161 million, indicating that the company’s underlying operations remained relatively resilient.

On July 29, 2026, Parsons reduced its full-year revenue guidance to between $6.2 billion and $6.5 billion, compared with its previous range of $6.5 billion to $6.8 billion. The company also lowered its adjusted EBITDA guidance to between $500 million and $560 million from $615 million to $675 million.

The guidance reduction triggered a sharp decline in Parsons Corporation’s stock price. Shares traded as low as $39.50 following the earnings announcement, marking a new 52-week low at that time.

Despite the weak earnings and lower guidance, Parsons reported several positive indicators. Contract awards rose 24% year over year, and the book-to-bill ratio reached 1.2x. This suggests that the company is securing new orders faster than it is completing existing work, signaling continued demand for its defense, infrastructure, and technology services.

Market Overview
ADGM
Adagio Medical Holdings, Inc.
$0.80
73.91%
TNMG
TNL Mediagene
$0.48
33.06%
ENSC
Ensysce Biosciences, Inc.
$0.38
37.17%
PLTR
Palantir Technologies Inc.
$162.66
29.45%
SXTC
China SXT Pharmaceuticals, Inc.
$0.12
60.08%
NVDA
NVIDIA Corporation
$211.94
2.56%
QNME
Lakeside Holding Limited
$0.69
-37.59%
AMIX
Autonomix Medical, Inc.
$19.50
434.25%
INTC
Intel Corp.
$100.86
10.84%
VTGN
VistaGen Therapeutics, Inc.
$0.30
22.45%